- BNF:
- not listed
- Status:
- Red
- Decision Date:
- September 2017
Comments
RED1,2,3:NICE TA465 - olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma. This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation. See MHRA guidance for further details
NHSE is the responsible commissioner for this drug and it is available via the Cancer Drug Fund.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again
